MPN Hub
By Scientific Education Support
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Scientific Education Support
Category: Education
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 25
Description
The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge in MPN, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
| Episode | Date |
|---|---|
|
ASH 2025 | Nuvisertib + momelotinib in patients with R/R MF: Phase I/II findings
|
Dec 17, 2025 |
|
ASH 2025 | What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?
|
Dec 15, 2025 |
|
How might extended-release formulations of ruxolitinib benefit patients with MF?
|
Nov 11, 2025 |
|
What are the unmet needs in the management of myelofibrosis-related anemia?
|
Oct 27, 2025 |
|
What is on the horizon for the treatment of myelofibrosis-related anemia?
|
Oct 22, 2025 |
|
How I treat myelofibrosis-related anemia
|
Oct 17, 2025 |
|
Novel targeted therapies for R/R MF: PIM1 kinase inhibition
|
Sep 03, 2025 |
|
Novel treatments: Momelotinib and luspatercept
|
May 19, 2025 |
|
Anemia in myelofibrosis: Q&A
|
May 12, 2025 |
|
Symposium | Sequencing therapies: Optimizing treatment for myelofibrosis
|
May 08, 2025 |
|
Symposium | The treatment landscape for patients with myelofibrosis and anemia
|
May 07, 2025 |
|
Symposium | Anemia in myelofibrosis: Impact on patient outcomes
|
May 06, 2025 |
|
Anemia as an unmet need: Impacts on QoL and survival outcomes
|
Apr 29, 2025 |
|
Clinical trial round-up: Treating anemia in patients with myelofibrosis
|
Mar 26, 2025 |
|
How might luspatercept benefit patients with myelofibrosis?
|
Sep 12, 2024 |
|
What more can be done to improve treatment for patients with polycythemia vera?
|
Aug 09, 2024 |
|
When to refer patients with MPN to clinical trials: Part II - Patients with MF
|
Mar 06, 2023 |
|
When to refer patients with MPN to clinical trials: Part I - Patients with ET/PV
|
Mar 02, 2023 |
|
Patient follow-up in myeloproliferative neoplasms: Best practices and myths
|
Feb 04, 2022 |
|
Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent PV?
|
Feb 03, 2021 |
|
Should we consider early testing and treatment for driver mutations acquired in childhood?
|
Jan 28, 2021 |
|
When can we safely discontinue interferon alpha therapy in patients with MPN?
|
Dec 17, 2020 |
|
Does interferon alpha prolong survival and prevent progression in patients with PV?
|
Dec 15, 2020 |
|
What do we know about the outcome of concomitant MPN and COVID-19?
|
Nov 06, 2020 |
|
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
|
Jun 30, 2020 |